George Ade Memorial Health Care Center | |
3623 East State Rd 16, Brook, Indiana 47922 | |
(219) 275-2531 | |
Name | George Ade Memorial Health Care Center |
---|---|
Location | 3623 East State Rd 16, Brook, Indiana |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 70 |
Occupancy Rate | 68.29% |
Medicare ID (CCN) | 155719 |
Legal Business Name | Board Of Commissioners Of Newton County |
Ownership Type | Government - County |
NPI Number | 1811086044 |
Organization Name | BOARD OF COMMISSIONERS OF NEWTON COUNTY |
Doing Business As | GEORGE ADE MEMORIAL HEALTH CARE CENTER |
Address | 3623 E State Road 16, Brook, IN 47922 |
Phone Number | 219-275-2531 |
News Archive
Nuline Pharmaceuticals, LLC announces the introduction of REMESENSE (dipotassium oxalate 3%) TOOTH DESENSITIZER, an Rx Class II medical device now available in the U.S. REMESENSE was introduced globally in 2008. It is presently sold in 16 countries, ranging from England and the European Union to Asia and Africa. Nuline expects to launch REMESENSE in Canada and other countries later this year or by early 2011.
Aalto University, the Finnish Meteorological Institute, VTT Technical Research Centre of Finland and the University of Helsinki have brought together a multidisciplinary group of researchers to model how the extremely small droplets that leave the respiratory tract when coughing, sneezing or talking are transported in air currents.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%.
Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients.
A surprising new preprint, released on the medRxiv* server, suggests that the beneficial effects of convalescent plasma (CP) in this disease stem not only from the presence of neutralizing antibodies, but also the immunomodulatory effects of this plasma that shapes the host immune response.
› Verified 8 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Nuline Pharmaceuticals, LLC announces the introduction of REMESENSE (dipotassium oxalate 3%) TOOTH DESENSITIZER, an Rx Class II medical device now available in the U.S. REMESENSE was introduced globally in 2008. It is presently sold in 16 countries, ranging from England and the European Union to Asia and Africa. Nuline expects to launch REMESENSE in Canada and other countries later this year or by early 2011.
Aalto University, the Finnish Meteorological Institute, VTT Technical Research Centre of Finland and the University of Helsinki have brought together a multidisciplinary group of researchers to model how the extremely small droplets that leave the respiratory tract when coughing, sneezing or talking are transported in air currents.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%.
Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients.
A surprising new preprint, released on the medRxiv* server, suggests that the beneficial effects of convalescent plasma (CP) in this disease stem not only from the presence of neutralizing antibodies, but also the immunomodulatory effects of this plasma that shapes the host immune response.
› Verified 8 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $9750 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 9.64 | 14.46 |
Percentage of long-stay residents who lose too much weight | 3.73 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 85.19 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 0.54 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 2.84 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 5.38 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 7.61 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 4.76 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 19.99 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 20.36 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 14.67 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
Percentage of short-stay residents who made improvements in function | 83.13 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 100 | 82.93 |
News Archive
Nuline Pharmaceuticals, LLC announces the introduction of REMESENSE (dipotassium oxalate 3%) TOOTH DESENSITIZER, an Rx Class II medical device now available in the U.S. REMESENSE was introduced globally in 2008. It is presently sold in 16 countries, ranging from England and the European Union to Asia and Africa. Nuline expects to launch REMESENSE in Canada and other countries later this year or by early 2011.
Aalto University, the Finnish Meteorological Institute, VTT Technical Research Centre of Finland and the University of Helsinki have brought together a multidisciplinary group of researchers to model how the extremely small droplets that leave the respiratory tract when coughing, sneezing or talking are transported in air currents.
Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its expanded offering of Powerlink® stent graft products. The approval covers 31 new sizes of Powerlink® main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%.
Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients.
A surprising new preprint, released on the medRxiv* server, suggests that the beneficial effects of convalescent plasma (CP) in this disease stem not only from the presence of neutralizing antibodies, but also the immunomodulatory effects of this plasma that shapes the host immune response.
› Verified 8 days ago
George Ade Memorial Health Care Center Location: 3623 East State Rd 16, Brook, Indiana 47922 Phone: (219) 275-2531 |